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Histone Deacetylase Inhibitor Romidepsin Enhances
Anti-Tumor Effect of Erlotinib in Non-small Cell Lung
Cancer (NSCLC) Cell Lines
Wei Zhang, PhD,* Michael Peyton, PhD,* Yang Xie, PhD,†‡ Junichi Soh, MD,*
John D. Minna, MD,*†§ Adi F. Gazdar, MD,*†¶ and Eugene P. Frenkel, MD†§
Introduction: Most epidermal growth factor receptor (EGFR) mu-
tant non-small cell lung cancers (NSCLCs) are sensitive to EGFR
tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, but
many EGFR wild type NSCLCs are resistant to TKIs. In this study,
we examined the effects of the histone deacetylase inhibitor, ro-
midepsin, in combination with erlotinib, in NSCLC cell lines and
xenografts.
Methods: For in vitro studies, nine NSCLC cell lines with varying
mutation status and histology were treated with erlotinib and ro-
midepsin alone or in combination. 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assays were
performed to determine the concentration that inhibits 50% (IC50)
value of each drug or the combination. For in vivo studies, NCI-
H1299 xenografts were inoculated subcutaneously into athymic
nude mice. Romidepsin and/or erlotinib were injected intraperitone-
ally after tumors developed and tumor sizes were measured.
Results:We found that romidepsin increased the sensitivity of erlotinib
synergistically in all nine NSCLC cell lines including EGFR and KRAS
wild type cell lines, KRAS mutant cell lines, and TKI resistant EGFR
mutant cell lines. This effect was partially due to enhanced apoptosis.
Furthermore, cotreatment of erlotinib and romidepsin inhibited NCI-
H1299 xenograft growth in athymic nude mice.
Conclusions: These observations support a role for the combination
of a histone deacetylase inhibitor and a TKI in the treatment of
NSCLCs.
Key Words: Erlotinib, Romidepsin, Non-small cell lung cancer,
Epidermal growth factor receptor, KRAS.
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The epidermal growth factor receptor (EGFR) belongs tothe EGFR family of tyrosine kinase receptors.1 Upon
activation, EGFR can promote cell proliferation and survival
through Ras/MEK/MAPK and/or PI3K/AKT signaling path-
ways.2 In recent years, non-small cell lung cancers (NSCLCs)
containing EGFR mutations have been found to be sensitive
to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib
(Tarceva) or gefitinib (Iressa), and these drugs have been
successfully used in the therapy for such patients.3,4 Unfor-
tunately, some patients with cancers containing EGFR muta-
tions develop resistance to TKIs after a period of time.
Although the mechanisms of resistance are not completely
understood, the existence of the secondary T790M mutation
activity appears to be the major mechanism.5 Furthermore,
most of the NSCLCs containing wild type EGFR receptor are
resistant to therapy with EGFR TKIs.6 In addition, the pres-
ence of KRAS mutations is associated with primary resis-
tance to TKIs.7 Thus, the role of erlotinib and gefitinib for the
treatment of NSCLC is limited.
Acetylation of histones plays an important role in
chromatin organization and gene expression.8 Acetylation is
determined by both histone acetyltransferases and histone
deacetylases (HDACs).9 HDACs remove the acetyl groups
from the lysine residues of the histone tail leading to com-
paction of chromatin and resultant repression of gene tran-
scription.9 Many nonhistone proteins can be HDAC sub-
strates such as p53, cMyc, Stat3, and Hsp90.10 Such potential
targets have provided a new strategy for the role of HDAC
inhibitors in cancer therapy. HDAC inhibitors can induce
growth arrest, differentiation, and apoptosis in tumor cells.11
Several HDAC inhibitors have been used in clinical trials.12
HDAC inhibitors are also excellent candidates for combina-
tion therapies. The HDAC inhibitor MS-275 was shown to
increase the sensitivity of gefitinib in NSCLC cell lines.13
Romidepsin (previously termed FK228), also known as
depsipeptide, is a natural cyclic peptide HDAC inhibitor. It
bears the molecular structure of depsipeptides, namely se-
quences of alternating amino- and hydroxy-carboxylic acid
residues.14 It has shown important inhibition of in vitro
growth of several tumor cell types including lung and prostate
cancers, lymphomas and leukemias.14–17 Romidepsin has re-
cently been studied in a clinical trial for treatment of lung
cancer.18 In this article, we investigated the effects of combining
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romidepsin and erlotinib on the sensitivity of EGFR wild type
and mutant NSCLC cell lines resistant to TKI therapy.
MATERIALS AND METHODS
Cell Lines and Drugs
Nine NSCLC cell lines (Table 1) were cultured in
RPMI 1640 (Life Technologies, Rockville, MD) supple-
mented with 5% fetal bovine serum and incubated in humid-
ified air and 5% CO2 at 37°C. The cell lines were established
by us, DNA fingerprinted, and free of mycoplasma by mo-
lecular tests (iNtRON Biotechnology, Korea). Romidepsin
was provided by Fujisawa Pharmaceutical Co. (Japan) (This
drug is now the property of Gloucester Co., MA). Erlotinib
(Tarceva) (OSI Pharmaceuticals, Inc., NY) was purchased
from UT Southwestern pharmacy.
DNA Isolation and Polymerase Chain Reaction
DNA was isolated from NSCLC cell lines and poly-
merase chain reaction was performed to determine the KRAS
and EGFR mutation status of each cell line according to
previously reported methods.19
MTS Assay
Drug sensitivity was measured by a 3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay (Promega, Madison, WI). Two  103
cells were seeded into eachwell of a 96-well microtiter plate. After
24 hours, the cells were treated with varying concentrations
(0.01–250 M) of erlotinib either in the absence or presence of
1 ng/ml romidepsin for 72 hours at 37°C. MTS solution was
added to each well, and the plates were incubated for 1 hour at
37°C. Optical density was measured at 490 nm using a Spec-
traMax 190 spectrophotometer (Molecular Devices, Sunnywale,
CA). Each experiment was carried out in eight replicate wells for
each drug concentration and repeated twice. The concentration
that inhibits 50% (IC50) value was defined as the concentration
needed for a 50% reduction in the absorbance calculated based
on the cell viability curves.
Apoptosis Assay
Apoptosis assay was preformed using cell death detec-
tion enzyme-linked immunosorbent assay (Roche Applied
Science, Indianapolis, IN) according to the manufacturer’s
protocol.
Xenograft Animal Models
Five  106 NCI-H1299 cells were resuspended in 200
l of RPMI 1640 and inoculated into the subcutaneous tissue
of the flanks of 25-week-old female Bagg Albino (BALB/c)
athymic nude mice (Charles river Laboratories, Wilmington,
MA). After tumors developed, romidepsin was injected in-
traperitoneally into the mice three times at 4 day intervals
(1.2 mg/kg body weight). Erlotinib was injected daily 5 days
a week (50 mg/kg body weight). The 1 phosphate-buffered
saline solution was used as a control solution. Tumor sizes
were measured and calculated from the following formula:
tumor size  L W2/2, where L and W represent the length
and the width of the tumor mass respectively.
Statistical Analysis
The Loewe additivity model was used to characterize
drug interaction between erlotinib and romidepsin. In this
model, the combination index (CI) was defined as CI 
d1/Dy,1  d2/Dy,2, where d1 and d2 are the doses of drug 1
and drug 2 in mixture, which produces an effect y, Dy,1 and
Dy,2 are the doses that produce the same effect y when
using alone.20,21 If the CI is equal, less than, or greater than
1, the combination dose (d1, d2) is called as additive,
synergistic or antagonistic, respectively. We also used
isobologram to illustrate the drug interaction geometrically.20
The Student’s t test was used to determine the potential
differences between the control group and the drug treat-
ment groups. p value 0.05 was considered statistically
significant.
TABLE 1. The IC50 Values of Romidepsin and Erlotinib in NSCLC Cell Lines
Histology
Mutation Statusa Erlotinib IC50  SD (M)
b
CIcEGFR KRAS
Romidepsinb
IC50  SD (ng/ml) No Romidepsin Romidepsin (1 ng/ml)
NCI-H1299 LC wt wt 4.6  0.2 90.0  2.2 2.6  0.01 0.25
NCI-2882 AD wt wt 1.6  0.04 115.0  3.7 1.9  0.4 0.65
HCC95 SQ wt wt 2.5  0.05 107.0  2.2 5.7  0.9 0.45
NCI-H23 AD wt mut 2.9  0.2 52.8  4.7 0.07  0.01 0.34
NCI-H157 SQ wt mut 1.6  0.02 75.0  3.0 0.3  0.03 0.63
NCI-H460 LC wt mut 2.1  0.07 105.3  4.4 1.7  0.2 0.50
NCI-H1975 AD mut wt 1.3  0.04 14.4  0.1 0.01  0.02 0.77
NCI-H820 AD mut wt 2.4  0.1 8.6  0.6 1.8  0.02 0.63
NCI-H1650 AD mut wt 4.9  0.3 28.3  1.4 4.8  0.8 0.37
a The mutation status of NSCLC cell lines were determined as described in Materials and Methods.
b The IC50 values of erlotinib and romidepsin were defined as the concentration needed for a 50% reduction in the absorbance calculated based on the cell viability curves.
c CI combination index. Values 1 are interpreted as synergism. (see Materials and Methods).
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; LC, large cell; AD, adenocarcinoma; SQ, squamous carcinoma; wt, wild type; mut, mutant; IC50,
concentration that inhibits 50%.
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RESULTS
Romidepsin Decreases the IC50 Values of
Erlotinib in NSCLC Cell Lines
Nine NSCLC cell lines of varying EGFR and KRAS
mutation status were chosen to study, including three cell
lines containing wild type EGFR and KRAS, three containing
mutant KRAS and three containing mutant EGFR but resis-
tant to TKIs. These NSCLC cell lines also had various
histologies including adenocarcinoma, squamous carcinoma
and large cell types (Table 1). We first examined the cyto-
toxicity of romidepsin in these NSCLC cell lines. The IC50
values of romidepsin ranged relatively little from 1.3 to 4.9
ng/ml (Table 1). As we selected NSCLC cell lines resistant to
TKI therapy for this study, the IC50 values for erlotinib (8.6–115
M) in these cell lines were considerably higher than the upper
value indicative of clinical sensitivity (2.5 M).22
For the combined treatment, the NSCLC cell lines were
treated with varying concentrations (0.01–250 M) of erlo-
tinib either in the absence or presence of 1 ng/ml romidepsin.
MTS assays were performed to determine the cell viability
and pairs of cell viability curves for each cell line are shown
in Figure 1A. We found that in the presence of 1 ng/ml
romidepsin, the IC50 values of erlotinib in six of nine NSCLC
cell lines examined decreased to less than 2.5 M. The CI has
been calculated, and 1 is considered synergism. The CI
values ranged from 0.25 to 0.77 in these cell lines (Table 1)
indicating that romidepsin and erlotinib showed synergism in
all the NSCLC cell lines examined. A dose-normalized IC50
isobologram was also made and shown in Figure 1B, illus-
trating the synergism geometrically.20
Combination of Romidepsin and Erlotinib
Induces Apoptosis in NSCLC Cell Lines
We next examined whether inducing apoptosis played a
role in the ability of romidepsin to sensitize lung cancer cells
to erlotinib. NCI-H1299 and NCI-H23 were treated with
either 5 M erlotinib or 1 ng/ml romidepsin, or the combi-
nation of these two drugs. After 72 hours, apoptosis was
determined using the cell death detection enzyme-linked
immunosorbent assay kit (Roche Applied Science). The
mono- and oligonucleosomes indicating apoptosis were de-
tected by antibodies against DNA and histones, and quanti-
fied by densitometry. As shown in Figure 2, while 5 M of
erlotinib and 1 ng/ml of romidepsin did not induce obvious
apoptosis, cotreatment of erlotinib and romidepsin caused a
2.3 (p 0.01) and 2.85 (p 0.002) fold increase in apoptosis
in NCI-H1299 and NCI-H23 cells, respectively.
Coadministration of Romidepsin and Erlotinib
Shows Inhibition on NCI-H1299 Cell Line
Xenografts
We further studied the combined effect of romidepsin
and erlotinib on tumor growth in vivo. We injected 5  106
NCI-H1299 cells subcutaneously into 20 female BALB/c
athymic nude mice. After visible tumors were seen at day 7,
the mice were divided into four groups (five mice per group).
One group was used as a phosphate-buffered saline treated
control. The other three groups were intraperitoneally in-
jected with either romidepsin alone, erlotinib alone or the
combination of both agents. Tumor size was measured at the
indicated days. After 20 days, the mice were killed. As shown in
Figure 3, at day 20, although erlotinib and romidepsin treatment
alone suppressed NCI-H1299 cell line xenograft growth to 72%
(p  0.47) and 43% (p  0.08) respectively compared with the
phosphate-buffered saline treated control group, these were not
statistically significant. Only the combined treatment inhibited
NCI-H1299 xenograft growth to 28%, causing a significant
decrease on tumor growth (p  0.04).
DISCUSSION
EGFR TKIs such as erlotinib and gefitinib have been
found to be efficient in the treatment of NSCLCs that express
mutant EGFR.3,4 However, resistance to TKIs develops in
some EGFR mutant NSCLCs. Furthermore, the majority of
NSCLCs containing wild type EGFR are resistant to EGFR
TKIs.22 To solve this problem, several new TKIs that have a
broader spectrum of kinase activities have been developed to
treat NSCLCs. For example, EXEL-7647 (XL647), a novel
spectrum-selective kinase inhibitor with potent activity
against the EGF and vascular endothelial growth factor re-
ceptor tyrosine kinase families, has shown efficiency in
therapy for both wild type and mutant EGFR in vitro and in
vivo.23 In addition, combinational therapies have been used to
overcome NSCLC resistance to EGFR TKIs. For example,
the combined use of erlotinib and the humanized vascular
endothelial growth factor receptor monoclonal antibody be-
vacizumab in advanced, chemotherapy-refractory NSCLCs
has shown promising results.24
Our data indicated that the HDAC inhibitor romidepsin
decreased the IC50 values of erlotinib in NSCLC cell lines
with wild type EGFR, including KRAS mutant cell lines
which are considered to be particularly resistant to EGFR
TKIs. These cell lines are composed of different histologic
types including adenocarcinoma, squamous carcinoma and
large cell types. Since most of EGFR mutant cell lines are
very sensitive to erlotinib, we examined three which exhibit
erlotinib resistance: NCI-H1975 and NCI-H820 cell lines
have a secondary T790M mutation, which is responsible for
the resistance5; NCI-H1650 cell line has a homozygous de-
letion of phosphatase and tensin homolog deleted on chro-
mosome 10 and therefore no detectible phosphatase and
tensin homolog deleted on chromosome 10 protein level,
which is associated with resistance to TKIs in human tu-
mors.25 We found that addition of romidepsin also increased
the sensitivity of erlotinib in TKI resistant EGFR mutant
NSCLC cell lines. Our data indicated that the HDAC inhib-
itor romidepsin and TKI erlotinib showed synergy in all nine
NSCLC cell lines examined.
The underlying mechanisms of this synergistic effect
are not known. Besides the secondary T790M mutation,
several other mechanisms have been proposed to explain the
resistance of NSCLCs to EGFR TKIs. It is reported that
epithelial to mesenchymal transition is a determinant of
sensitivity of NSCLCs to EGFR inhibition.26 Epithelial to
mesenchymal transition is characterized by the combined loss
of epithelial cell junction proteins such as E-cadherin and the
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FIGURE 1. Romidepsin synergistically increased the sensitivity of erlotinib in non-small cell lung cancer (NSCLC) cell lines. A, Nine
NSCLC cell lines were treated with varying concentrations of erlotinib either in the absence or presence of romidepsin (1 ng/ml) for 72
hours. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
assay and representative pairs of cell viability curves are shown. B, The dose-normalized isobologram for erlotinib and
romidepsin with normalization of dose with IC50 to unity on both x and y axis. All the points represent the drug combination
that yield 50% cell reduction. If the point falls on the lower left part of the graph, synergism is indicated.
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gain of mesenchymal markers such as vimentin or fibronec-
tin.27 Restoring E-cadherin expression has been shown to
increase sensitivity to EGFR inhibitors in NSCLCs.13 Persis-
tent activity of MAPK or/and AKT pathway has also been
related to EGFR TKI resistance. Treatment of specific inhib-
itors of MAPK or AKT pathway can increase the sensitivity
of NSCLC cell lines to TKIs.6 Romidepsin can regulate
expression of many genes. It was reported that romidepsin
treatment led to altered expression of cyclin A, cyclin E, and
p21, reduced protein levels of ErbB1, ErbB2, and Raf-1.28
Furthermore, romidepsin inhibited ERK1/2 MAPK activi-
ties.28 Modification of important players in signal transduc-
tion pathways, or other important cellular events by romidep-
sin may account for the synergy.
In our studies, in the presence of romidepsin at the
concentration of 1 ng/ml, the IC50 values of erlotinib in six
out of nine NSCLC cell lines decreased to 2.5 M, which
is considered to be sensitive to erlotinib in vitro,22 and
approximately corresponds to the plasma steady-state con-
centration of erlotinib in patients treated with a dose of 150
mg daily.29 The concentration of romidepsin used for our in
vitro combination treatment is far below 25 ng/ml that cor-
responds to 50% of the free drug concentration in plasma
from lung cancer patients receiving this drug at the maximum
tolerated dose.28 This suggested that the combined treatment
of romidepsin and erlotinib will be beneficial in clinical trials.
A recent study indicated that although romidepsin exhibited
modest clinical efficacy in lung cancer patients at the tested
dose and schedule, the biologic effects mediated by romidep-
sin supported the evaluation of this HDAC inhibitor in
combination with other targeted agents in lung cancer pa-
tients.18 Our data indicates that combination of erlotinib with
romidepsin may benefit NSCLC patients not predicted to
respond to TKI therapy.
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